SciFluor is focused on creating proprietary best-in-class drugs based on well-understood pathways in areas of significant medical need such as ophthalmology, fibrosis and neurology.

Our lead drug candidate, SF0166, is a small molecule integrin antagonist designed to treat retinal disease, including Diabetic Macular Edema (DME) and neovascular Age-related Macular Degeneration (wet-AMD) via topical (eye drop) administration to the eye. SF0166 has been studied in two multi-center, randomized, Phase I/II trials, in patients with DME and in patients with wet-AMD. In addition to this drug candidate, SciFluor is pursuing earlier-stage projects in fibrosis and neurology.

We strategically incorporate fluorine into small molecules with a goal of creating drug candidates that have superior potency, selectivity and pharmacokinetic properties and thus have the potential to be best-in-class drugs. We have an extensive and expanding patent estate covering our drug candidates and methods of their use.

SciFluor is a subsidiary of Allied Minds (ALM.L). Allied Minds plc (Allied Minds or the Company or the Group) is an IP commercialization company focused on early stage company creation and development within the technology and life science sectors. With origination relationships spanning US federal laboratories, universities, and leading US corporations, Allied Minds sources, operates and funds a portfolio of companies to generate long-term value for its investors and stakeholders. Based in Boston, Allied Minds supports its businesses with capital, management, expertise and shared services. For more information, please visit


SciFluor News

SciFluor Announces Appointment of Robert Dempsey to Board of Directors
read more >

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >